# ACE-106

Source: https://onco.cc/drugs/ace-106/  
OnCo record `ace-106` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ACE-106 is an experimental oral small-molecule inhibitor from Acerand Therapeutics, in phase 2 trials for advanced solid tumours and BRCA-mutated ovarian, breast and prostate cancer.

## Summary

ACE-106 (ACE-86225106) is an oral small-molecule inhibitor from Acerand Therapeutics. A highly selective PARP1 inhibitor taken by mouth. Its furthest stage is phase 2, for advanced solid tumours and BRCA-mutated ovarian, breast and prostate cancer (registry conditions). ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06380660 (sponsor Acerand Therapeutics (Shanghai)) active, not recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Also known as: ACE-86225106
- Tags: pipeline; ctgov-ingest
- Code: ACE-106
- Modality: Oral small-molecule inhibitor
- Mechanism: A highly selective PARP1 inhibitor taken by mouth.

## Sources

- Acerand Therapeutics: acerand.com: https://www.acerand.com/news.html
- Acerand Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06380660
- ClinicalTrials.gov: trials of ACE-106: https://clinicaltrials.gov/search?intr=ACE-106

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [Acerand Therapeutics](https://onco.cc/companies/acerand-therapeutics/)
- trials: [Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06380660/)

---
JSON: https://onco.cc/api/v1/entities/ace-106.json